Progress of PD-1/PD-L1 inhibitors in lymphoma treatment / 中国肿瘤临床

ABSTRACT

In recent years, tumor biological immunotherapy has rapidly become a hot topic in the field of cancer research owing to its remarkable therapeutic effects. Programmed death-1 (PD-1) and its ligand (PD-L1) are overexpressed in a variety of tumor cells and are involved in tumorigenesis, development, invasion, and metastasis. Therefore, blocking the PD-1/PD-L1 signaling pathway has be-come a promising new target for tumor immunotherapy. At present, PD-1/PD-L1 inhibitors have exhibited remarkable therapeutic ef-fects in the treatment of lymphoma. This paper reviews the current status of clinical research on these drugs in order to enhance the understanding of the mechanism of PD-1/PD-L1 signaling pathway and the applications of relevant antibodies for the treatment of lym-phoma.